secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001628280-25-023410
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab Q1 revenue up 22% to $106.5M; operating loss narrows 20%; on track for Q4 profitability
--------------------------------------------------------------------------------

- Product revenue $105.7M (+21% YoY); VYVGART $18.1M, ZEJULA $49.5M, NUZYRA $15.1M.
- Adjusted operating loss $37.1M, improved 25% YoY; net loss $48.4M vs $53.5M prior year.
- Cash $857.3M; reaffirms FY2025 revenue guidance $560M-$590M.
- ZL-1310 (DLL3 ADC) pivotal study in ES-SCLC expected H2 2025; ASCO data June 2.
- Discontinued ZL-1102 (IL-17) Phase 2 trial after interim analysis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000162828025023410/0001628280-25-023410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000162828025023410/zlab-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-023410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer